Evaluation of CD206 agonists in diabetic retinopathy

CD206激动剂在糖尿病视网膜病变中的评价

• 批准号: 10688959
• 负责人: Mark Henderson
• 金额: $ 14.62万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10688959
• 关键词: Agonist; Blindness; Blood; Blood Glucose; Blood Pressure; Blood Vessels; Cholesterol; Diabetes Mellitus; Diabetic Retinopathy; Disease; Evaluation; Eye; Eye diseases; Fibrosis; Inflammation; Laser Surgery; Operative Surgical Procedures; Patients; Peptides; Pharmacologic Substance; Prevention; Retina; Retinal Diseases; Symptoms; Therapeutic; Tissues; United States; diabetic; experimental study; in vivo; mouse model; prevent; retina blood vessel structure; small molecule; stem

The condition called diabetic retinopathy stems from damage to the blood vessels of the retina caused by diabetes. This is the most common diabetic eye disease and a leading cause of blindness in the United States. No treatment is available in the early stages of the disease, which also frequently have no symptoms. This project seeks to evaluate the capacity of CD206 agonists to prevent or reverse fibrosis associated with diabetic retinopathy, a leading cause of blindness. During this period the team evaluated the activity of several CD206 agonists (peptide and small molecule) in a mouse model of diabetic retinopathy developed by Dr. Uemara. Initial in vivo experiments showed promising results with a reduction of inflammation and prevention of fibrosis in the eye.

糖尿病视网膜病变是由糖尿病引起的视网膜血管损伤引起的。这是最常见的糖尿病眼病，也是美国失明的主要原因。在疾病的早期阶段没有治疗方法，通常也没有症状。该项目旨在评估CD206激动剂预防或逆转糖尿病视网膜病变相关纤维化的能力，糖尿病视网膜病变是导致失明的主要原因。 在此期间，研究小组评估了几种CD206激动剂（肽和小分子）在Uemara博士开发的糖尿病视网膜病变小鼠模型中的活性。最初的体内实验显示了减少炎症和预防眼睛纤维化的有希望的结果。